Probiotic treatment for allergic rhinitis and gut health
The Effectiveness of Weizmannia Coagulans BC99 in Alleviating Allergic Rhinitis in Adults and Its Impact on the Gut Microbiota.
This study is testing if a probiotic can help people with allergic rhinitis feel better by reducing symptoms like sneezing and nasal congestion while also improving gut health.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 70 (estimated) |
| Ages | 18 Years to 65 Years |
| Sex | All |
| Sponsor | Wecare Probiotics Co., Ltd. Industry-sponsored |
| Locations | 1 site (Luoyang, Henan) |
| Trial ID | NCT06680102 on ClinicalTrials.gov |
What this trial studies
This clinical trial evaluates the effectiveness of weizmannia coagulans BC99, a probiotic, in alleviating symptoms of allergic rhinitis while also improving gut microbiota. Participants aged 18 to 65 who meet specific diagnostic criteria for allergic rhinitis will be enrolled. The study aims to assess symptom relief, including sneezing and nasal congestion, and monitor any adverse reactions. The intervention involves administering the probiotic alongside maltodextrin as a control.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18 to 65 who have been diagnosed with allergic rhinitis and experience persistent symptoms.
Not a fit: Patients who have recently used medications affecting gut microbiota may not benefit from this study.
Why it matters
Potential benefit: If successful, this treatment could provide significant relief for patients suffering from allergic rhinitis and improve their gut health.
How similar studies have performed: While the specific probiotic approach may be novel, similar studies have shown promise in using probiotics to manage allergic conditions.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Voluntarily and in writing, sign an informed consent form agreeing to participate in this study; 2. Able to complete the study as required by the trial protocol; 3. Age between 18 and 65 years old; 4. Meet the diagnostic criteria for allergic rhinitis established in the "Chinese Guidelines for the Diagnosis and Treatment of Allergic Rhinitis (2022 Revised Edition)"; 5. Symptoms: Presence of two or more symptoms such as sneezing, watery rhinorrhea, nasal itching, and nasal congestion, with daily symptoms lasting or accumulating for more than 1 hour, which may be accompanied by eye itching, tearing, and redness of the eyes and other ocular symptoms; 6. Signs: Pale and edematous nasal mucosa, which may be accompanied by watery secretions. Exclusion Criteria: 1. Use of drugs affecting the gut microbiota (including antimicrobial agents, probiotics, intestinal mucosal protective agents, traditional Chinese patent medicines, etc.) for more than 1 week within 1 month prior to screening; 2. Patients with coexisting pulmonary tuberculosis; 3. Patients with coexisting allergic asthma; 4. Patients with nasal polyps or severe nasal septum deviation; 5. Patients with severe systemic diseases or malignant tumors; 6. Individuals with congenital genetic diseases or congenital immunodeficiency diseases; 7. Regular use of probiotics or prebiotics within 6 months prior to the screening period; 8. Patients with severe gastrointestinal diseases (including severe diarrhea, inflammatory bowel diseases, etc.); 9. Individuals with metabolic syndrome (including obesity, dyslipidemia, hypertension, diabetes, etc.); 10. Patients with sinusitis, otitis media, or respiratory tract infections; 11. Individuals allergic to any components of the probiotics used in this trial; 12. Pregnant or lactating women or those planning to conceive in the near future; 13. Those who discontinue the test sample or take other medications midway, making it impossible to determine efficacy or with incomplete data; 14. Recent use of products similar to the test function, affecting the judgment of the results; 15. Participants who cannot participate in the trial due to their own reasons; 16. Other participants deemed ineligible by the researcher.
Where this trial is running
Luoyang, Henan
- School of Food and Bioengineering, Henan University of Science and Technology — Luoyang, Henan, China (Recruiting)
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.